Five Prime Therapeutics Profit Margin

Five Prime Therapeutics (FPRX) currently reports a profit margin of -639.92% as of December 2020. That compares with -922.43% in the prior-year period — up 30.6% year over year. That is below the Healthcare sector average of 14.41%. Use the charts on this page to explore Five Prime Therapeutics's profit margin history and peer comparisons.

Five Prime Therapeutics's profit margin increased from -922.43% to -639.92% — a 30.6% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Five Prime Therapeutics's profit margin of -639.92% is lower than the Healthcare sector average of 14.41%. That is roughly 4539.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Five Prime Therapeutics's current -639.92% should be judged against Healthcare norms (sector average: 14.41%) and against FPRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -639.92%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for Five Prime Therapeutics, and consider following FPRX for alerts when major investors trade the stock.